

CITATION REPORT

List of articles citing

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial

DOI: 10.1016/s1470-2045(17)30691-5
Lancet Oncology, The, 2017, 18, 1610-1623.

Source: <https://exaly.com/paper-pdf/67452528/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
121	Bevacizumab in adjuvant treatment of non-small-cell lung cancer. <i>Lancet Oncology, The</i> , 2017 , 18, 1558-1569	25	4
120	Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. 2018 , 41, 1113-1117		3
119	Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. 2018 , 13, 767-778		16
118	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. 2018 , 378, 1976-1986		865
117	Anti-Angiogenics: Their Value in Lung Cancer Therapy. 2018 , 41, 172-180		22
116	Recent progress in systemic treatment for lung cancer. 2018 , 24, 355-366		7
115	The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review). 2018 , 17, 8019-8030		25
114	Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine. 2018 , 10, 1364-1369		4
113	Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?. 2018 , 10, S2114-S2118		1
112	Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?. 2018 , 7, S179-S182		
111	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. 2018 , 13, 1818-1831		73
110	Les traitements pré-opératoires des cancers bronchiques non à petites cellules : standards actuels et perspectives. 2018 , 10, 285-291		
109	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. 2018 , 10, 1758835918772810		11
108	Discovering novel valid biomarkers and drugs in patient-centric genomic trials: the new epoch of precision surgical oncology. 2018 , 23, 1848-1872		7
107	Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIIC. 2018 , 13, 156-169		0
106	Changes in store for early-stage non-small cell lung cancer. 2019 , 11, 2117-2125		6
105	Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study. 2019 , 121, 372-377		9

104	Chemotherapy for Lung Cancer in the Era of Personalized Medicine. 2019 , 82, 179-189	25
103	Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents. 2019 , 9, 9204	2
102	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. 2019 , 8,	2
101	Survival Before and After Direct Surgical Quality Feedback in a Population-Based Lung Cancer Cohort. 2019 , 107, 1487-1493	5
100	MS-275 potentiates the effect of YM-155 in lung adenocarcinoma via survivin downregulation induced by miR-138 and miR-195. 2019 , 10, 1355-1368	1
99	Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis. 2019 , 2, e193684	4
98	Focus on Recommendations for the Management of Non-small Cell Lung Cancer. 2019 , 42, 1230-1239	2
97	Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201). 2019 , 132, 1-8	6
96	Adjuvant and Neoadjuvant Therapy in NonSmall-Cell Lung Cancer. 2019 , 35-55	
95	miRNA-223 is an anticancer gene in human non-small cell lung cancer through the PI3K/AKT pathway by targeting EGFR. 2019 , 41, 1549-1559	10
94	Vessel co-option in cancer. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 469-493	19.4 158
93	Immunotherapy in patients with early stage resectable nonsmall cell lung cancer. 2019 , 31, 13-17	21
92	The Current Status of Immunotherapy in Thoracic Malignancies. 2019 , 45-75	
91	PD-1 Blockade in Early-Stage Lung Cancer. 2019 , 70, 425-435	15
90	Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives. 2019 , 20, 1-6	21
89	Vessel co-option and resistance to anti-angiogenic therapy. 2020 , 23, 55-74	33
88	Chemotherapy remains a cornerstone in the treatment of nonsmall cell lung cancer. 2020 , 32, 63-67	15
87	Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study. 2020 , 18, 263	3

86	Les traitements péri-opératoires des cancers bronchiques non à petites cellules (CNPC) : standards actuels et perspectives. 2020 , 12, 2S86-2S93	
85	Effects of microRNA regulation on antiangiogenic therapy resistance in non-small cell lung cancer. 2020 , 131, 110557	5
84	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. 2020 , 9, 2059-2073	6
83	Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!. 2020 , 8, 1199	
82	Adjuvant Osimertinib in -Mutated Non-Small-Cell Lung Cancer. 2020 , 383, 1780-1782	9
81	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. 2020 , 22, 109	4
80	Randomized Phase III Study of Irinotecan Plus Cisplatin Versus Etoposide Plus Cisplatin for Completely Resected High-Grade Neuroendocrine Carcinoma of the Lung: JCOG1205/1206. 2020 , 38, 4292-4301	14
79	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. 2020 , 38, 2187-2196	32
78	Adjuvant Chemotherapy. 2020 , 30, 179-185	0
77	The Story of Angiogenesis Inhibitors in Non-small-cell Lung Cancer: The Past, Present, and Future. 2020 , 21, 308-313	13
76	Conquering lung cancer: current status and prospects for the future. 2020 , 26, 283-290	19
75	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. 2020 , 15, 709-740	77
74	5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming. 2020 , 122, 1194-1204	7
73	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. 2020 , 26, 3525-3536	9
72	Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers. 2020 , 3, e202488	4
71	Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers. 2020 , 7, 3-15	2
70	Cancer in the time of COVID-19: expert opinion on how to adapt current practice. 2020 , 55,	8
69	Clinical Significance of Station 3A Lymph Node Dissection in Patients with Right-Side Non-Small-Cell Lung Cancer: A Retrospective Propensity-Matched Analysis. 2021 , 28, 194-202	2

68	Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity. 2021 , 29, 658-670	2
67	2020 Innovation-Based Optimism for Lung Cancer Outcomes. 2021 , 26, e454-e472	4
66	Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III -Mutant Non-Small-Cell Lung Cancer. 2021 , 5, 325-332	1
65	Immune-related adverse event profile of combination treatment of PD-(L)1 checkpoint inhibitors and bevacizumab in non-small cell lung cancer patients: data from the FDA adverse event reporting system. 2021 , 10, 2614-2624	1
64	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with mutation (West Japan Oncology Group 11719L/ADJUST study). 2021 , 13, 1758835920987647	2
63	Molecular biomarkers in early stage lung cancer. 2021 , 10, 1165-1185	9
62	Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics. 2021 , 23, 31	6
61	Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report. 2021 , 12, 1256-1259	1
60	Lung cancer chemotherapy using nanoparticles: Enhanced target ability of redox-responsive and pH-sensitive cisplatin prodrug and paclitaxel. 2021 , 136, 111249	4
59	Acceptability and feasibility of S-1 plus cisplatin adjuvant chemotherapy for completely resected non-small cell lung cancer: an open-label, single arm, multicenter, phase 2 trial. 2021 , 13, 2224-2232	1
58	Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 547-557	19.4 15
57	Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report. 2021 , 57,	
56	A Case of Granulocyte Colony-stimulating Factor-producing Pulmonary Pleomorphic Carcinoma with Metastasis to the Small Intestine in Which Surgery and Bevacizumab-based Chemotherapy Were Effective. 2021 , 61, 177-183	
55	Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. 2021 , 13, e08253	2
54	Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. 2021 , 16, 960-967	1
53	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). 2021 , 13, 727-734	2
52	The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer. 2021 , 47, e20210230	
51	Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials. 2021 , 1-14	1

50	Role of adjuvant therapy in T1-2N0 resected non-small cell lung cancer. 2021 ,	1
49	Targeted therapy moves to earlier stages of non-small-cell lung cancer: emerging evidence, controversies and future challenges. 2021 , 17, 4011-4025	3
48	Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients. 2021 , 158, 115-125	1
47	Effectiveness and safety of bevacizumab in extensive-disease small cell lung cancer: a systemic review and meta-analysis. 2021 , 9, 1285	0
46	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. 2021 , 398, 1344-1357	84
45	Surgical challenges in multimodal treatment of N2-stage IIIa non-small cell lung cancer. 2021 , 51, 333-344	4
44	Advances in the Treatment of Stage III Non-Small Cell Lung Cancer. 2020 , 41, 211-222	9
43	Adjuvant therapy of operable nonsmall cell lung cancer: an update. 2021 , 33, 47-54	4
42	Colonization with multi-drug-resistant organisms negatively impacts survival in patients with non-small cell lung cancer. 2020 , 15, e0242544	2
41	Les traitements péri-opératoires des cancers bronchiques non à petites cellules (CNPC) : standards actuels et perspectives. 2021 , 13, 2S89-2S96	
40	International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIa non-small-cell lung cancer. 2021 ,	3
39	Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment. 2021 , 31, 399-406	0
38	Les traitements péri-opératoires des cancers bronchiques non à petites cellules (CNPC): standards actuels et perspectives. 2019 , 11, 248-254	
37	Risk of Hypertension Associated with Antivasular Endothelial Growth Factor Monoclonal Antibodies: A Meta-Analysis From 51088 Patients with Cancer. 2020 , 22,	1
36	Targeted adjuvant therapy in non-small cell lung cancer: trick or treat?. 2021 , 58,	
35	First and Second Line Chemotherapeutic Regimens for Non-Small Cell Lung Carcinomas - The Efficacy of Platinum, Non-Platinum and Combination Therapy: A Literature Review. 2020 , 12, e11619	1
34	Src-Homology 2 Domain-Containing Phosphatase 2 in Resected Mutation-Positive Lung Adenocarcinoma. 2020 , 1, 100084	1
33	Recent advances in early stage lung cancer. 2021 , 7, 163-174	2

32	Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer.. 2022 , JCO2101589		
31	Bevacizumab Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgically Resected NSCLC.. 2022 , 3, 100274		0
30	Management of Early-Stage Resected Non-Small Cell Lung Cancer: Consensus Statement of the Lung cancer Consortium.. 2022 , 31, 100538		
29	Adjuvant therapy for early-stage non-small cell lung cancer: The breaking of a new dawn.. 2022 ,		1
28	Advances in Neoadjuvant and Adjuvant Immunotherapy and Targeted Therapy for Resectable NSCLC.		
27	Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA-IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study.. 2022 , 9, 316016		
26	Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.. 2022 , 20, 49		6
25	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.. 2022 , 128, 105816		
24	Expert consensus on perioperative immunotherapy in non-small cell lung cancer: an editorial.. 2021 , 10, 4322-4327		
23	Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.. 2021 , JCO2102528		7
22	Advances and controversies in the management of early stage non-small cell lung cancer.. 2021 , 12, 1089-1100		1
21	Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases.. <i>Molecules</i> , 2022 , 27,	4.8	4
20	Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 174, 103703	7	
19	Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer. <i>Drugs</i> ,	12.1	1
18	Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis. <i>BMJ Open</i> , 2022 , 12, e057098	3	0
17	Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 10,	5.7	2
16	When can we be confident of surgical cure with ctDNA?. <i>Nature Reviews Clinical Oncology</i> ,	19.4	0
15	Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). <i>Cell Death and Disease</i> , 2022 , 13,	9.8	0

- 14 Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. 12, ○
- 13 PROZ Associated with Sorafenib Sensitivity May Serve as a Potential Target to Enhance the Efficacy of Combined Immunotherapy for Hepatocellular Carcinoma. **2022**, 13, 1535 ○
- 12 Integration of New Systemic Adjuvant Therapies for Non-Small Cell Lung Cancer: Role of the Surgeon. **2022**, ○
- 11 Les traitements péri-opératoires des cancers bronchiques non à petites cellules (CNPC) : standards actuels et perspectives. **2022**, 14, 2S99-2S108 ○
- 10 Cancer of the Lung. 1-29 ○
- 9 Tumor Angiogenesis. 1-30 ○
- 8 Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. **2022**, 7, 100605 ○
- 7 Gender is a non-negligible risk factor affecting the overall survival time of NSCLC patients: a nationwide population-based study. ○
- 6 Immune Checkpoint Inhibitors for Solid Tumors in the Adjuvant Setting: Current Progress, Future Directions, and Role in Transplant Oncology. **2023**, 15, 1433 ○
- 5 Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials. **2023**, 21, ○
- 4 Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience. **2023**, 45, 1071-1079 ○
- 3 Endostatin and Cancer Therapy: A Novel Potential Alternative to Anti-VEGF Monoclonal Antibodies. **2023**, 11, 718 ○
- 2 Current status and future of anti-angiogenic drugs in lung cancer. ○
- 1 Perioperative Therapy for Resectable Non-Small-Cell Lung Cancer: Weighing Options for the Present and Future. ○